Sixmo 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0015 
C.I.11.a - Introduction of, or change(s) to, the 
16/02/2023 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
/202205 
buprenorphine (implant) 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202111 
buprenorphine (implant) 
IA/0012 
B.II.d.2.a - Change in test procedure for the finished 
25/04/2022 
n/a 
product - Minor changes to an approved test 
procedure 
IB/0011 
B.I.b.2.a - Change in test procedure for AS or 
08/03/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
/202105 
buprenorphine (implant) 
IB/0009 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
17/12/2021 
28/11/2022 
SmPC, 
life of the finished product - As packaged for sale 
(supported by real time data) 
Labelling and 
PL 
IA/0008 
B.III.1.a.2 - Submission of a new/updated or 
02/08/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
buprenorphine (implant) 
IAIN/0006/G 
This was an application for a group of variations. 
17/03/2021 
n/a 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202005 
buprenorphine (implant) 
N/0004 
Minor change in labelling or package leaflet not 
27/11/2020 
25/01/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/09/2020 
25/01/2022 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10778
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
/201911 
buprenorphine (implant) 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
